



## Trivalent Filovirus Vaccine

### Filo

#### Description

The Trivalent Filovirus Vaccine is intended to protect against aerosolized exposure to filoviruses; Ebola Sudan, Ebola Zaire, and Marburg viruses. The objective end product would contain all three vaccine components in a single vaccine formulation.

#### Mission

The aim of this work is to generate a trivalent vaccine that will simultaneously protect against multiple and diverse members of the Filoviridae family. Currently, no FDA-licensed vaccines or therapeutics protect against Ebola or Marburg viruses. Even with supportive care, death occurs in 50 to 90 percent of people infected.

#### Capabilities

- Biological Prophylaxis
- Target Capability: Onset of protection 30 days after initial vaccination
- Target Capability: Duration of protection for one year

#### Users

US Navy, US Marine Corps, US Coast Guard, US Army, US Air Force

#### Status

Technology Development - Anticipated Fielding: FY 2024 Q4

This Fact Sheet was cleared for public release on 6/15/2015.

Point of Contact: Chemical, Biological, Radiological, & Nuclear Information Resource Center (CBRN IRC), CBRN.IRC@mail.mil,  
Toll Free: 1-800-831-4408, Commercial: (309) 782-7349, DSN: 793-7349, Fax: (309) 782-1919